USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
PHOENIX PHARMACOLOGICS, INC.
Address:
PHOENIX PHARMACOLOGICS, INC.
ASTECC FACILITY #A-217
LEXINGTON, KY 40506
Phone:
(859) 257-9027
URL:
N/A
EIN:
232927291
DUNS:
N/A
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $300,454.00 5
SBIR Phase II $1,192,428.00 2

Award List:

ARGININE DEIMINASE AS AN ANTI-CANCER THERAPY

Award Year / Program / Phase:
1999 / SBIR / Phase I
Award Amount:
$100,492.00
Agency:
HHS
Principal Investigator:
Mike A. Clark
Abstract:
Not Available A novel high temperature inductive turbine blade tip clearance sensor is proposed to meet the needs indicated by the Air Force and corroborated by several turbine manufacturers for research and development as well as production applications. The design will meet the goals of measuring… More

Arginine deiminase as an Anti-Cancer Therapy

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Mike A. Clark
Abstract:
DESCRIPTION: The distinctive arginine requirement of hepatocellular carcinomas and malignant melanomas provides the basis for a new potential chemotherapy. Just as acute lymphocytic leukemia cells require asparagine and E. coli asparaginase enzyme can be used to effect a… More

Arginine deiminase as an Anti-Cancer Therapy

Award Year / Program / Phase:
2001 / SBIR / Phase II
Award Amount:
$383,600.00
Agency:
HHS
Principal Investigator:
Mike A. Clark
Abstract:
DESCRIPTION: The distinctive arginine requirement of hepatocellular carcinomas and malignant melanomas provides the basis for a new potential chemotherapy. Just as acute lymphocytic leukemia cells require asparagine and E. coli asparaginase enzyme can be used to effect a… More

MODIFIED TNF-ALPHA: AN ANTI CANCER THERAPY

Award Year / Program / Phase:
2001 / SBIR / Phase I
Award Amount:
$99,962.00
Agency:
HHS
Principal Investigator:
Mike A. Clark
Abstract:
DESCRIPTION (PROVIDED BY APPLICANT): The long-term goal of the proposed research is the development of effective anti-cancer agents, modified human tumor necrosis factor-alphas (hTNFas). TNFa is a potent anti-neoplastic agent but its therapeutic application has been… More

PRECLINICAL DEVELOPMENT OF URICASE-PEG 20

Award Year / Program / Phase:
2002 / SBIR / Phase I
Award Amount:
$100,000.00
Agency:
HHS
Principal Investigator:
Abstract:
Hyperuricemia (elevated serum uric acid) results in gouty arthritis and chronic renal disease. Severe hyperuricemia can occur following cancer chemotherapy (tumor lysis syndrome) and organ transplantation (most common in heart and kidney transplant patients) which may result in acute uric acid… More

Preclinical Development of PEG-TNF

Award Year / Program / Phase:
2004 / SBIR / Phase II
Award Amount:
$808,828.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Unformulated human tumor necrosis factor( (huTNF() has anti-tumor activity in mice, but there is little difference between the effective and lethal doses. Systemic administration of unformulated huTNFalpha has been tested in humans. All studies indicated the… More

Preclinical Development of PEG-TNF

Award Year / Program / Phase:
2004 / SBIR / Phase I
Award Amount:
$0.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Unformulated human tumor necrosis factor( (huTNF() has anti-tumor activity in mice, but there is little difference between the effective and lethal doses. Systemic administration of unformulated huTNFalpha has been tested in humans. All studies indicated the… More